$1.66
-0.04 (-2.35%)
Open$1.71
Previous Close$1.70
Day High$1.72
Day Low$1.66
52W High$2.57
52W Low$1.15
Volume—
Avg Volume568.8K
Market Cap79.03M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,862.0% upside
Current
$1.66
$1.66
Target
$32.57
$32.57
$26.16
$32.57 avg
$50.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 10.28M | 9.86M | 9.80M |
| Net Income | -1,154,434 | -865,846 | -1,110,362 |
| Profit Margin | -11.2% | -8.8% | -11.3% |
| EBITDA | -1,433,621 | -1,413,990 | -1,277,421 |
| Free Cash Flow | -904,387 | -870,700 | -861,997 |
| Rev Growth | +11.1% | +6.2% | +2.7% |
| Debt/Equity | 0.32 | 0.28 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |